Company / Gross Margin
BioNexus Gene Lab Corp Gross Margin History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
14.6%
FY2025
5-year range
11.5% / 17.0%
FY2021-FY2025
Trend
+7.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin has fluctuated over the past 7 years, ranging from 11.5% in FY2022 to 44.0% in FY2019.
Based on SEC 10-K filings.
14.6% in FY2025 with a 5-year CAGR of -0.5%.
Improved from 13.6% to 14.6% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +3.1pp
- 5-Year Change
- -0.5pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, gross margin increased 7.8% year-over-year.
- Peak gross margin was recorded in FY2019.
- Lowest gross margin in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 14.6% | +7.8% |
| FY2024 | 13.6% | -0.4% |
| FY2023 | 13.6% | +18.1% |
| FY2022 | 11.5% | -32.1% |
| FY2021 | 17.0% | +12.3% |
| FY2020 | 15.1% | -65.7% |
| FY2019 | 44.0% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026